AYTU · Aytu BioPharma, Inc.
The AI's read
The offer gives shareholders a set cash payment if the deal closes. It still depends on a majority of shares being tendered and other closing conditions. Aytu's business results were mixed. EXXUA and pediatric sales grew, but ADHD sales fell, and the company moved from profit to loss. Its adjusted measure of operating results also showed a wider loss. The purchase offer is the strongest signal for shareholders because it names a cash price, but completion is not assured.